Trastuzumab deruxtecan versus chemotherapy for patients with HER2-low advanced breast cancer: A US-based cost-effectiveness analysis

Background: In recent years, the rise of antibody–drug conjugates (ADCs) has changed the treatment paradigm for patients with HER2-low advanced breast cancer (ABC). DESTINY-Breast04 (NCT03734029) has demonstrated the antitumor activity of trastuzumab deruxtecan (T-DXd). However, the balance between...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Youwen, Liu, Kun, Zhu, Xiaolu, Qin, Qun, Zhu, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650214/
https://www.ncbi.nlm.nih.gov/pubmed/36386213
http://dx.doi.org/10.3389/fphar.2022.1025243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650214/
https://www.ncbi.nlm.nih.gov/pubmed/36386213
http://dx.doi.org/10.3389/fphar.2022.1025243

Ejemplares similares